Cell Pathways,Inc.

As of June 12, 2003, Cell Pathways, Inc. was acquired by OSI Pharmaceuticals Inc. Cell Pathways, Inc. is a biopharmaceutical company that discovers and develops products for the treatment and prevention of precancerous lesions and cancer. The company's products include Gelclair, a bioadhesive oral gel that provides rapid and long-lasting relief from oral pain. Additionally, the company’s clinical development product candidates include Aptosyn, a clinical development candidate used as a single agent and in combination with chemotherapy for cancer and precancerous conditions; and CP461, a clinical development candidate used as a single agent and in combination with cancer chemotherapy.